Escitaloprám oxalate 20 mg
Pro Research Analysisby 
Searched over 200M research papers
Escitalopram Oxalate 20 mg: Bioavailability, Bioequivalence, and Clinical Efficacy
Bioavailability and Bioequivalence of Escitalopram Oxalate 20 mg Tablets
Bioequivalence in Healthy Populations
Several studies have investigated the bioequivalence of escitalopram oxalate 20 mg tablets, comparing generic formulations to the reference brand, Lexapro®. In a study conducted with healthy Chinese subjects, both male and female, the generic formulation was found to be bioequivalent to Lexapro® under both fasting and fed conditions. The pharmacokinetic parameters, including AUC0-t, AUC0-∞, and Cmax, fell within the bioequivalence acceptance criteria of 80.00% to 125.00% .
Similarly, a study in healthy Indian male subjects under fasting conditions confirmed the bioequivalence of a generic formulation to Lexapro®. The 90% confidence intervals for Cmax and AUC0-t were within the regulatory acceptance limits, indicating that the generic formulation is interchangeable with the reference product . Another study with healthy volunteers in Colombia also demonstrated bioequivalence between a generic formulation and Lexapro®, with pharmacokinetic parameters such as Cmax and AUC0-96 within the accepted range .
Pharmacokinetic Parameters
The pharmacokinetic profiles of escitalopram oxalate 20 mg tablets have been extensively studied. In the Indian study, the maximum plasma concentrations (Cmax) were 26.386 ± 5.54 ng/mL for the test formulation and 24.430 ± 3.52 ng/mL for the reference. The areas under the plasma concentration-time curve (AUC0-∞) were 854.241 ± 91.22 ng·hr/mL for the test and 825.135 ± 1.37 ng·hr/mL for the reference . In the Chinese study, the Cmax values were 9.85 ± 1.79 ng/mL for the test and 9.92 ± 2.14 ng/mL for the reference, with AUC0-∞ values of 428.40 ± 140.25 ng·hr/mL and 413.73 ± 144.81 ng·hr/mL, respectively .
Clinical Efficacy and Safety of Escitalopram
Treatment of Major Depressive Disorder (MDD)
Escitalopram, a selective serotonin reuptake inhibitor (SSRI), is widely used for the treatment of major depressive disorder (MDD). It has shown superior efficacy compared to placebo and is at least as effective as other SSRIs and SNRIs in improving depression scores on scales such as the Montgomery-Asberg Depression Rating Scale (MADRS) and the Hamilton Depression Rating Scale (HAM-D) .
High-Dose Escitalopram
An open-label pilot study explored the efficacy and safety of escitalopram at doses up to 50 mg in patients with MDD who did not respond to citalopram. The study found that 35% of patients achieved remission, with some requiring doses up to 50 mg. However, tolerability declined at doses above 40 mg, with 26% of patients unable to tolerate the 50 mg dose. Common adverse events included headache, nausea, and diarrhoea .
Conclusion
Escitalopram oxalate 20 mg tablets, both generic and brand formulations, have been shown to be bioequivalent in various healthy populations, ensuring their interchangeability. Clinically, escitalopram is effective in treating MDD, with a predictable safety profile. Higher doses may benefit some patients, although tolerability issues need to be considered. Further studies are warranted to explore the long-term efficacy and safety of high-dose escitalopram.
Sources and full results
Most relevant research papers on this topic